DK2994157T3 - Tafa4-forbindelser og anvendelser deraf til behandling af smerte - Google Patents

Tafa4-forbindelser og anvendelser deraf til behandling af smerte Download PDF

Info

Publication number
DK2994157T3
DK2994157T3 DK14723045.2T DK14723045T DK2994157T3 DK 2994157 T3 DK2994157 T3 DK 2994157T3 DK 14723045 T DK14723045 T DK 14723045T DK 2994157 T3 DK2994157 T3 DK 2994157T3
Authority
DK
Denmark
Prior art keywords
pain
treatment
tafa4
compounds
tafa4 compounds
Prior art date
Application number
DK14723045.2T
Other languages
Danish (da)
English (en)
Inventor
Aziz Moqrich
Marie-Claire Delfini
Annabelle Mantilleri
Original Assignee
Centre National De La Recherche Scient (Cnrs)
Université D'aix-Marseille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National De La Recherche Scient (Cnrs), Université D'aix-Marseille filed Critical Centre National De La Recherche Scient (Cnrs)
Application granted granted Critical
Publication of DK2994157T3 publication Critical patent/DK2994157T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A01K2217/077—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out heterozygous knock out animals displaying phenotype
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Environmental Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Genetics & Genomics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK14723045.2T 2013-05-06 2014-05-06 Tafa4-forbindelser og anvendelser deraf til behandling af smerte DK2994157T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13305592.1A EP2801369A1 (en) 2013-05-06 2013-05-06 TAFA4 compounds and uses thereof for treating pain
PCT/EP2014/059247 WO2014180853A1 (en) 2013-05-06 2014-05-06 Tafa4 compounds and uses thereof for treating pain

Publications (1)

Publication Number Publication Date
DK2994157T3 true DK2994157T3 (da) 2020-08-24

Family

ID=48428409

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14723045.2T DK2994157T3 (da) 2013-05-06 2014-05-06 Tafa4-forbindelser og anvendelser deraf til behandling af smerte

Country Status (8)

Country Link
US (2) US9884088B2 (enExample)
EP (2) EP2801369A1 (enExample)
JP (1) JP6487419B2 (enExample)
CN (1) CN105209056B (enExample)
CA (2) CA2910652C (enExample)
DK (1) DK2994157T3 (enExample)
ES (1) ES2813629T3 (enExample)
WO (1) WO2014180853A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107430121B (zh) * 2015-03-13 2020-06-23 希森美康株式会社 受试物质的检测方法及在该方法中使用的试剂盒
CN111683592B (zh) * 2017-10-30 2023-11-03 加利福尼亚大学董事会 使用电化学传感器对分析物进行无校正的体内测量
KR102866162B1 (ko) * 2018-04-24 2025-10-01 주식회사 뉴라클사이언스 신경병성 통증의 치료를 위한 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리의 용도
ES2943136T3 (es) * 2018-09-27 2023-06-09 Inst Nat Sante Rech Med Polipéptido de TAFA4 para su uso para reducir la inflamación cutánea
CN109596818B (zh) * 2018-12-13 2024-03-19 丁蓉 一种基于电生理学分析当归四逆汤预防奥沙利铂神经毒性机制的研究方法
WO2021156310A1 (en) * 2020-02-04 2021-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Tafa4 polypeptide or polynucleotide for treating inflammatory disease
JP7729824B2 (ja) * 2020-02-13 2025-08-26 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ マルガリン酸はｐｉｅｚｏ２媒介性疼痛を低減させる
TWI759788B (zh) * 2020-07-08 2022-04-01 台灣粒線體應用技術股份有限公司 萃取保護液用於自細胞分離粒線體並維持粒線體活性的用途
CA3239578A1 (en) 2021-12-17 2023-06-22 Stephane GAILLARD Peptides and methods for use in treating pain
MX2024007794A (es) * 2021-12-20 2024-07-02 Amgen Inc Peptidos de union a dll3 y usos de los mismos.
EP4499163A1 (en) * 2022-03-24 2025-02-05 Baxter International Inc. Dialysis system having thermoelectric heating
AR129441A1 (es) 2022-05-25 2024-08-28 Tafalgie Therapeutics Péptidos y métodos para el tratamiento del dolor
AU2023278710A1 (en) * 2022-05-31 2024-12-12 Elisigen Inc. Composition for treating retinal or macular diseases
CN120813839A (zh) 2023-02-17 2025-10-17 Naos生命科学研究所 一种用于筛选能够提高皮肤耐受阈值的生态生物型化合物的方法
WO2025116606A1 (ko) * 2023-11-30 2025-06-05 주식회사 뉴라클제네틱스 신규한 케모카인-유사 단백질 단편
WO2026119983A1 (en) 2024-12-03 2026-06-11 Tafalgie Therapeutics Peptides for use in treating pain, wounds and inflammatory diseases
CN121249875B (zh) * 2025-10-13 2026-03-20 上海交通大学医学院附属仁济医院 外周神经系统中的Mas相关G蛋白耦联受体D在缓解阿片类药物耐受中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090077680A1 (en) * 2000-06-12 2009-03-19 Alejandro Abuin Genetically Engineered and Photyped Mice and Stem Cell Clones for Producing the Same
WO2006013462A2 (en) * 2004-07-30 2006-02-09 Nsgene A/S Growth factors nsg28, nsg30, and nsg32

Also Published As

Publication number Publication date
JP2016519138A (ja) 2016-06-30
US9884088B2 (en) 2018-02-06
EP2994157A1 (en) 2016-03-16
EP2994157B1 (en) 2020-07-01
US20160113996A1 (en) 2016-04-28
CA2910652A1 (en) 2014-11-13
JP6487419B2 (ja) 2019-03-20
CA3235916A1 (en) 2014-11-13
US20180110829A1 (en) 2018-04-26
CA2910652C (en) 2024-05-28
EP2801369A1 (en) 2014-11-12
ES2813629T3 (es) 2021-03-24
CN105209056A (zh) 2015-12-30
WO2014180853A1 (en) 2014-11-13
CN105209056B (zh) 2018-01-23

Similar Documents

Publication Publication Date Title
DK3035926T3 (da) Forbindelser og fremgangsmåder til behandling af en epilepsilidelse
DK3329884T3 (da) Implanterbar indretning til behandling af glaukom
DK3039146T3 (da) Produkter og fremgangsmåder til behandling af amyotrofisk lateral sklerose
DK3033086T3 (da) Kombinationsterapi til behandling af cancer
DK2983787T3 (da) Fremgangsmåde til behandling af posttraumatisk stresssygdom
DK3508502T5 (da) Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer
DK3024497T3 (da) Fremgangsmåder og præparater til behandling af hjernesygdomme
DK2968208T3 (da) Behandling af kataplexi
DK3054976T3 (da) Anvendelse af semaphorin-4d-bindende molekyler til behandling af aterosklerose
DK4000608T3 (da) Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf
DK2954051T3 (da) Modificeret kapsid til genoverførsel til behandling af nethinden
DK3007695T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
DK2967049T3 (da) Metoder, forbindelser og sammensætninger til behandlingen af angiotensin relaterede sygdomme
DK3811943T3 (da) Forbindelse til anvendelse til behandling af øjenlidelser
DK3021838T3 (da) Behandling af fedme
DK3076976T3 (da) Fremgangsmåder til behandling af cancer
DK2976359T4 (da) Fremgangsmåder til behandling af osteogenesis imperfecta
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK2764881T3 (da) System til medicinsk behandling
DK3025586T3 (da) Sammensætning til bekæmpelse af plantesygdomme og anvendelse deraf
DK3030549T3 (da) Pyridazinonforbindelser og anvendelser deraf
DK3089707T3 (da) Vævtransplantater og fremgangsmåder til fremstilling og brug af samme
DK3077467T3 (da) Sikkativsammensætning og anvendelse deraf
DK2964767T3 (da) Toksingener og fremgangsmåder til anvendelse deraf
DK3069720T3 (da) Farmakologisk sammensætning indeholdende glutarimid-derivater og anvendelse deraf til behandling af eosinofile sygdomme